Early to raise

Vivo's $100 million sweet spot for early stage U.S. and China investments

After watching big biotech and pharma companies snatch up an increasing number of preclinical or Phase I biotechs in the last three and a half years, Vivo Capital has created a vehicle to make investments far upstream of where the firm traditionally puts money to work.

The new $100 million

Read the full 504 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers